Renaissance Technologies
TPTX

Renaissance Technologies’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Renaissance Technologies’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,400
Closed -$557K – 4584
2022
Q2 		$557K Sell
7,400
-11,300
-60% -$502K ﹤0.01% 3104
2022
Q1 		$502K Buy
+18,700
New +$628K ﹤0.01% 3192
2021
Q3 		– Sell
-142,700
Closed -$11.1M – 3990
2021
Q2 		$11.1M Buy
142,700
+24,400
+21% +$1.8M 0.01% 1101
2021
Q1 		$11.2M Buy
118,300
+84,200
+247% +$10M 0.01% 1123
2020
Q4 		$4.16M Sell
34,100
-63,000
-65% -$6.9M ﹤0.01% 1709
2020
Q3 		$8.48M Sell
97,100
-54,100
-36% -$3.77M 0.01% 1250
2020
Q2 		$9.77M Buy
151,200
+53,806
+55% +$3.1M 0.01% 1237
2020
Q1 		$4.35M Buy
+97,394
New +$5.17M ﹤0.01% 1656

Renaissance Technologies's TPTX Position: Q3 2022 in Review

Renaissance Technologies sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 7,400 shares — an estimated $557K sold.

Renaissance Technologies first reported a position in TPTX in Q1 2020 and held it in 8 quarters. The position peaked at $11.2M in Q1 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Renaissance Technologies reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Renaissance Technologies sold 7,400 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $557K.
  • Renaissance Technologies first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2020 and held it in 8 quarters.
  • Renaissance Technologies's Turning Point Therapeutics, Inc. Common Stock position peaked at $11.2M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Renaissance Technologies's 13F filing for Q3 2022, filed 14 Nov 2022.